ETHIC Act
- Bill Number
- H.R. 3269
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Commerce
- Status
- Introduced
- Latest Action
- 2025-05-08: Referred to the House Committee on the Judiciary.
- Last Updated
- 2026-06-24T08:10:26Z
AI-Generated Summary
Purpose
The Eliminating Thickets to Increase Competition Act (ETHIC Act), H.R. 3269, aims to reduce "patent thickets"—a strategy where companies file multiple related patents to delay competition from lower-cost generic drugs or biosimilar products. By limiting the number of patents that can be enforced in lawsuits against these competitors, the bill seeks to promote fairer market entry and increase competition in the pharmaceutical industry.
Key Provisions
- Limitation on Patent Assertions: In infringement lawsuits under 35 U.S.C. § 271(e) (which covers activities related to developing generic drugs or biosimilars), a patent holder can assert no more than one patent per Patent Group against specific parties.
- Affected Parties: This restriction applies to:
- Companies submitting or holding approvals for generic drugs under abbreviated pathways (e.g., ANDA under 21 U.S.C. § 355(j) or 505(b)(2)).
- Companies submitting or holding licenses for biosimilar biological products (under 42 U.S.C. § 262(k)).
- Entities making, using, selling, or importing these approved generics or biosimilars.
- Prohibition on Additional Lawsuits: Once a patent from a Patent Group is asserted, no further lawsuits using other patents from the same group can be filed against the same party.
- Definition of Patent Group: A group consists of two or more commonly owned patents or applications linked through "disclaimers" under 35 U.S.C. § 253 (terminal disclaimers, which are legal statements tying the expiration dates of related patents to prevent extending market exclusivity).
- Patents that reference the same disclaimer or are referenced by it form the same group.
- Applicability: The rules apply to applications submitted on or after the date the Act is enacted.
Significant Changes to Existing Law
- Amends 35 U.S.C. § 271(e)(7) by adding a new paragraph that introduces the one-patent-per-group limit, which did not previously exist.
- Targets the use of terminal disclaimers to bundle patents, restricting how these bundles can be weaponized in litigation to block generics or biosimilars.
- Does not alter the validity of patents or disclaimers themselves but limits their enforcement in specific infringement actions related to drug approvals.
Potential Impacts
- On Citizens: Could accelerate the availability of affordable generic drugs and biosimilars, potentially lowering prescription drug prices and improving access to healthcare for patients.
- On Government Agencies: The Food and Drug Administration (FDA) may see faster approval processes for generics and biosimilars due to reduced litigation barriers, indirectly supporting public health goals without direct changes to FDA operations.
- On International Relations: Minimal direct impact, though it may influence global pharmaceutical trade by making U.S. markets more accessible to international generic manufacturers, potentially affecting export strategies of U.S. drug companies.
- Broader Market Effects: Encourages innovation in competitive drug development while curbing strategies that extend monopolies, possibly leading to more dynamic pricing in the $500+ billion U.S. pharmaceutical sector.
Main Stakeholders Affected
- Pharmaceutical Innovators (Brand-Name Companies): Face restrictions on using multiple linked patents to defend market exclusivity, potentially reducing their ability to delay generic entry and impacting revenue from blockbuster drugs.
- Generic and Biosimilar Manufacturers: Benefit from fewer lawsuits and lower legal costs, enabling quicker market entry and more predictable competition.
- Consumers and Patients: Primary beneficiaries through potential cost savings on medications.
- Healthcare Providers and Insurers: Could see reduced drug costs, aiding budget management for treatments.
- U.S. Patent and Trademark Office (USPTO): Indirectly affected, as the bill influences how terminal disclaimers are used in patent strategies without changing USPTO's examination processes.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens the balance between patent incentives for innovation and antitrust-like concerns over market abuse, building on the Hatch-Waxman Act (1984) framework for generic approvals. It may lead to more streamlined court challenges but could invite disputes over what constitutes a "Patent Group."
- Constitutional: Aligns with the U.S. Constitution's Patent Clause (Article I, Section 8), which promotes "progress of science and useful arts" by limiting patent enforcement that stifles competition, without infringing on property rights in patents.
- Political: Bipartisan support (introduced by representatives from both parties) highlights cross-aisle interest in drug pricing reform. If enacted, it could set a precedent for further interventions in patent law to address industry practices, amid ongoing debates over healthcare affordability.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Arrington, Jodey C. [R-TX-19]
Cosponsors (9)
Rep. Doggett, Lloyd [D-TX-37], Rep. Issa, Darrell [R-CA-48], Rep. Jayapal, Pramila [D-WA-7], Rep. Pfluger, August [R-TX-11], Rep. Dingell, Debbie [D-MI-6], Rep. Tlaib, Rashida [D-MI-12], Rep. Harshbarger, Diana [R-TN-1], Rep. García, Jesús G. "Chuy" [D-IL-4], Rep. Craig, Angie [D-MN-2]
Recent Actions
- 2025-05-08: Referred to the House Committee on the Judiciary.
- 2025-05-08: Introduced in House
- 2025-05-08: Introduced in House
Bill Versions
- Eliminating Thickets to Increase Competition Act — issued 2025-05-08 — PDF (4 pages)